BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz LL, Abou-Alfa GK. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol. 2010;28:2889-2895. [PMID: 20458042 DOI: 10.1200/jco.2009.25.9895] [Cited by in Crossref: 186] [Cited by in F6Publishing: 118] [Article Influence: 16.9] [Reference Citation Analysis]
Number Citing Articles
1 Shindoh J, Kobayashi Y, Kawamura Y, Akuta N, Kobayashi M, Suzuki Y, Ikeda K, Hashimoto M. Microvascular Invasion and a Size Cutoff Value of 2 cm Predict Long-Term Oncological Outcome in Multiple Hepatocellular Carcinoma: Reappraisal of the American Joint Committee on Cancer Staging System and Validation Using the Surveillance, Epidemiology, and End-Results Database. Liver Cancer 2020;9:156-66. [PMID: 32399430 DOI: 10.1159/000504193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
2 Shu QH, Ge YS, Ma HX, Gao XQ, Pan JJ, Liu D, Xu GL, Ma JL, Jia WD. Prognostic value of polarized macrophages in patients with hepatocellular carcinoma after curative resection. J Cell Mol Med 2016;20:1024-35. [PMID: 26843477 DOI: 10.1111/jcmm.12787] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
3 Zhang Q, Chen X, Zang Y, Zhang L, Chen H, Wang L, Niu Y, Ren X, Shen Z, Shang L. The survival benefit of liver transplantation for hepatocellular carcinoma patients with hepatitis B virus infection and cirrhosis. PLoS One. 2012;7:e50919. [PMID: 23236406 DOI: 10.1371/journal.pone.0050919] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
4 Fu X, Zhu Y, Zheng B, Zou Y, Wang C, Wu P, Wang J, Chen H, Du P, Liang B, Fang L. KIFC1, a novel potential prognostic factor and therapeutic target in hepatocellular carcinoma. Int J Oncol 2018;52:1912-22. [PMID: 29620256 DOI: 10.3892/ijo.2018.4348] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
5 Ji X, Zhao Y, Zhu X, Shen Z, Li A, Chen C, Chu X. Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer With Oligometastases, Oligoprogression, or Local Control of Dominant Tumors. Front Oncol 2020;10:595781. [PMID: 33585211 DOI: 10.3389/fonc.2020.595781] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liu Q, Li J, Liu F, Yang W, Ding J, Chen W, Wei Y, Li B, Zheng L. A radiomics nomogram for the prediction of overall survival in patients with hepatocellular carcinoma after hepatectomy. Cancer Imaging 2020;20:82. [PMID: 33198809 DOI: 10.1186/s40644-020-00360-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Yang F, Ma L, Yang Y, Liu W, Zhao J, Chen X, Wang M, Zhang H, Cheng S, Shen F, Wang H, Zhou W, Cao G. Contribution of Hepatitis B Virus Infection to the Aggressiveness of Primary Liver Cancer: A Clinical Epidemiological Study in Eastern China. Front Oncol 2019;9:370. [PMID: 31179237 DOI: 10.3389/fonc.2019.00370] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
8 Yi PS, Zhang M, Zhao JT, Xu MQ. Liver resection for intermediate hepatocellular carcinoma. World J Hepatol 2016;8:607-15. [PMID: 27190577 DOI: 10.4254/wjh.v8.i14.607] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
9 Yuan C, Hu Z, Wang K, Zou S. Development and Validation a Nomogram for Predicting Overall Survival in Patients With Intrahepatic Cholangiocarcinoma. Front Surg 2021;8:659422. [PMID: 34079814 DOI: 10.3389/fsurg.2021.659422] [Reference Citation Analysis]
10 Fox R, Berhane S, Teng M, Cox T, Tada T, Toyoda H, Kumada T, Kagebayashi C, Satomura S, Johnson PJ. Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model. Br J Cancer. 2014;110:2090-2098. [PMID: 24691419 DOI: 10.1038/bjc.2014.130] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
11 Chen YJ, Chi CW, Su WC, Huang HL. Lapatinib induces autophagic cell death and inhibits growth of human hepatocellular carcinoma. Oncotarget 2014;5:4845-54. [PMID: 24947784 DOI: 10.18632/oncotarget.2045] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
12 Zhang YF, Shi M, Lu LH, Wang L, Guo RP. Selecting an Optimal Staging System for Intermediate-Stage Hepatocellular Carcinoma: Comparison of 9 Currently Used Prognostic Models. J Hepatocell Carcinoma 2021;8:253-61. [PMID: 33907695 DOI: 10.2147/JHC.S305581] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wagle P, Narkhede R, Desai G, Pande P, Kulkarni DR, Varty P. SURGICAL MANAGEMENT OF LARGE HEPATOCELLULAR CARCINOMA: THE FIRST SINGLE-CENTER STUDY FROM WESTERN INDIA. Arq Bras Cir Dig 2020;33:e1505. [PMID: 33237158 DOI: 10.1590/0102-672020190001e1505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Li H, He Y, Huang L, Luo H, Zhu X. The Nomogram Model Predicting Overall Survival and Guiding Clinical Decision in Patients With Glioblastoma Based on the SEER Database. Front Oncol 2020;10:1051. [PMID: 32676458 DOI: 10.3389/fonc.2020.01051] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
15 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014.122] [Cited by in Crossref: 247] [Cited by in F6Publishing: 237] [Article Influence: 35.3] [Reference Citation Analysis]
16 Ge MH, Cao J, Wang JY, Huang YQ, Lan XB, Yu B, Wen QL, Cai XJ. Nomograms predicting disease-specific regional recurrence and distant recurrence of papillary thyroid carcinoma following partial or total thyroidectomy. Medicine (Baltimore) 2017;96:e7575. [PMID: 28746205 DOI: 10.1097/MD.0000000000007575] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
17 Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, Rashid A, Abbruzzese JL, Morris JS. V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer. 2011;117:2478-2488. [PMID: 24048796 DOI: 10.1002/cncr.25791] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
18 Choi C, Choi GH, Kim TH, Tanaka M, Meng MB, Seong J. Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. Liver Cancer 2014;3:405-16. [PMID: 26280002 DOI: 10.1159/000343861] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
19 Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol. 2015;7:406-424. [PMID: 25848467 DOI: 10.4254/wjh.v7.i3.406] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
20 Endo M, Nishikawa H, Kita R, Kimura T, Ohara Y, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H, Osaki Y. Comparison of five staging systems in hepatocellular carcinoma treated with sorafenib: A single-center experience. Mol Clin Oncol 2016;4:515-22. [PMID: 27073653 DOI: 10.3892/mco.2016.755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
21 Zhao LY, Li CC, Jia LY, Chen XL, Zhang WH, Chen XZ, Yang K, Liu K, Wang YG, Xue L, Zhang B, Chen ZX, Chen JP, Zhou ZG, Hu JK. Superiority of lymph node ratio-based staging system for prognostic prediction in 2575 patients with gastric cancer: validation analysis in a large single center. Oncotarget 2016;7:51069-81. [PMID: 27363014 DOI: 10.18632/oncotarget.9714] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
22 Fu YP, Yi Y, Cai XY, Sun J, Ni XC, He HW, Wang JX, Lu ZF, Huang JL, Cao Y, Zhou J, Fan J, Qiu SJ. Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. Br J Cancer. 2016;114:767-776. [PMID: 27002937 DOI: 10.1038/bjc.2016.47] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
23 Liu LL, Zhu LB, Zheng JN, Bi TD, Ma JF, Wang LN, Yao L. Development and assessment of a predictive nomogram for the progression of IgA nephropathy. Sci Rep 2018;8:7309. [PMID: 29743598 DOI: 10.1038/s41598-018-25653-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M, Saeki C, Tajiri H. The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer 2013;13:52. [PMID: 23374755 DOI: 10.1186/1471-2407-13-52] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 7.0] [Reference Citation Analysis]
25 Zhao L, Han W, Yang X, Zhao D, Niu P, Gao X, Wu Z, Zhang X, Li Z, Ji G, Chen Y. Exceeding 30 ELNs is strongly recommended for pT3-4N0 patients with gastric cancer: A multicenter study of survival, recurrence, and prediction model. Cancer Sci 2021;112:3266-77. [PMID: 34080256 DOI: 10.1111/cas.15003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One 2014;9:e90929. [PMID: 24603710 DOI: 10.1371/journal.pone.0090929] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
27 Liu K, Feng F, Chen XZ, Zhou XY, Zhang JY, Chen XL, Zhang WH, Yang K, Zhang B, Zhang HW, Zhou ZG, Hu JK. Comparison between gastric and esophageal classification system among adenocarcinomas of esophagogastric junction according to AJCC 8th edition: a retrospective observational study from two high-volume institutions in China. Gastric Cancer 2019;22:506-17. [PMID: 30390154 DOI: 10.1007/s10120-018-0890-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
28 Shao Y, Ning Z, Chen J, Geng Y, Gu W, Huang J, Pei H, Shen Y, Jiang J. Prognostic nomogram integrated systemic inflammation score for patients with esophageal squamous cell carcinoma undergoing radical esophagectomy. Sci Rep 2015;5:18811. [PMID: 26689680 DOI: 10.1038/srep18811] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
29 Zhang MX, Gan W, Jing CY, Zheng SS, Zhang J, Shen HJ, Xu X, Lin JJ, Zhang BH, Qiu SJ. Overexpression of interleukin-35 in intrahepatic cholangiocarcinoma is a prognostic indicator after curative resection. Cancer Sci 2018;109:1195-206. [PMID: 29446854 DOI: 10.1111/cas.13535] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
30 Liao W, Zhang J, Zhu Q, Qin L, Yao W, Lei B, Shi W, Yuan S, Tahir SA, Jin J, He S. Preoperative Neutrophil-to-Lymphocyte Ratio as a New Prognostic Marker in Hepatocellular Carcinoma after Curative Resection. Transl Oncol 2014;7:248-55. [PMID: 24704092 DOI: 10.1016/j.tranon.2014.02.011] [Cited by in Crossref: 45] [Cited by in F6Publishing: 51] [Article Influence: 6.4] [Reference Citation Analysis]
31 Adhoute X, Penaranda G, Raoul JL, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H, Bourlière M. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol 2016;8:703-15. [PMID: 27330679 DOI: 10.4254/wjh.v8.i17.703] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
32 Wan G, Gao F, Chen J, Li Y, Geng M, Sun L, Liu Y, Liu H, Yang X, Wang R. Nomogram prediction of individual prognosis of patients with hepatocellular carcinoma. BMC Cancer. 2017;17:91. [PMID: 28143427 DOI: 10.1186/s12885-017-3062-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
33 op den Winkel M, Nagel D, Sappl J, op den Winkel P, Lamerz R, Zech CJ, Straub G, Nickel T, Rentsch M, Stieber P. Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One. 2012;7:e45066. [PMID: 23071507 DOI: 10.1371/journal.pone.0045066] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
34 Xu R, Zhou B, Hu P, Xue B, Gu D, Li X, Tang Q. Development and validation of prognostic nomograms for patients with colon neuroendocrine neoplasms. World J Surg Oncol 2021;19:233. [PMID: 34364382 DOI: 10.1186/s12957-021-02338-8] [Reference Citation Analysis]
35 Shi M, Zhou B, Yang SP. Nomograms for predicting overall survival and cancer-specific survival in young patients with pancreatic cancer in the US based on the SEER database. PeerJ 2020;8:e8958. [PMID: 32322444 DOI: 10.7717/peerj.8958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
36 Chen ZY, Wei W, Guo ZX, Peng LX, Shi M, Li SH, Xiao CZ, Zhong C, Qian CN, Guo RP. Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts. Br J Cancer 2014;110:733-40. [PMID: 24495874 DOI: 10.1038/bjc.2013.781] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
37 Huang J, Xu L, Luo Y, He F, Zhang Y, Chen M. The inflammation-based scores to predict prognosis of patients with hepatocellular carcinoma after hepatectomy. Med Oncol. 2014;31:883. [PMID: 24535607 DOI: 10.1007/s12032-014-0883-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
38 Diouf M, Bonnetain F, Barbare JC, Bouché O, Dahan L, Paoletti X, Filleron T. Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma. Oncologist 2015;20:62-71. [PMID: 25542450 DOI: 10.1634/theoncologist.2014-0175] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
39 Huo J, Wu L, Zang Y. Development and Validation of a Metabolic-related Prognostic Model for Hepatocellular Carcinoma. J Clin Transl Hepatol 2021;9:169-79. [PMID: 34007798 DOI: 10.14218/JCTH.2020.00114] [Reference Citation Analysis]
40 Kaseb AO, Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, Hassan MM, Lin E, Xiao L, El-Deeb AS, Rashid A. I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology. 2011;80:373-381. [PMID: 21822028 DOI: 10.1159/000329040] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
41 Xiao S, Feng F, Liu N, Liu Z, Guo Y, Lian X, Zhang H. Preoperative Albumin Level Is Superior To Albumin-Globulin Ratio As A Predicting Indicator In Gastric Cancer Patients Who Underwent Curative Resection. Cancer Manag Res 2019;11:9931-8. [PMID: 31819631 DOI: 10.2147/CMAR.S230741] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Cao X, Zheng YZ, Liao HY, Guo X, Li Y, Wang Z, Zhang L, Wang XD, Wang X. A clinical nomogram and heat map for assessing survival in patients with stage I non-small cell lung cancer after complete resection. Ther Adv Med Oncol 2020;12:1758835920970063. [PMID: 33224277 DOI: 10.1177/1758835920970063] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
43 Tang X, Liu S, Liu Y, Lin X, Zheng T, Liu X, Qiu J, Hua K. Circulating serum exosomal aHIF is a novel prognostic predictor for epithelial ovarian cancer. Onco Targets Ther 2019;12:7699-711. [PMID: 31571921 DOI: 10.2147/OTT.S220533] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
44 Chan AW, Chan SL, Mo FK, Wong GL, Wong VW, Cheung YS, Chan HL, Yeo W, Lai PB, To KF. Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinoma. Dis Markers. 2015;2015:564057. [PMID: 25737613 DOI: 10.1155/2015/564057] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
45 Zhengqi Q, Zezhi G, Lei J, He Q, Jinyao P, Ying A. Prognostic role of PHYH for overall survival (OS) in clear cell renal cell carcinoma (ccRCC). Eur J Med Res 2021;26:9. [PMID: 33468235 DOI: 10.1186/s40001-021-00482-1] [Reference Citation Analysis]
46 Chen Y, Jiang S, Lu Z, Xue D, Xia L, Lu J, Wang H, Xu L, Li L, Li G. Development and verification of a nomogram for prediction of recurrence-free survival in clear cell renal cell carcinoma. J Cell Mol Med 2020;24:1245-55. [PMID: 31782902 DOI: 10.1111/jcmm.14748] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
47 Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer 2013;119:3334-42. [PMID: 23821538 DOI: 10.1002/cncr.28209] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
48 Ma HX, Shu QH, Pan JJ, Liu D, Xu GL, Li JS, Ma JL, Jia WD, Yv JH, Ge YS. Expression of Kindlin-1 in human hepatocellular carcinoma and its prognostic significance. Tumour Biol 2015;36:4235-41. [PMID: 25592379 DOI: 10.1007/s13277-015-3060-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
49 Shao YY, Lu LC, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems. Br J Cancer. 2012;107:1672-1677. [PMID: 23059748 DOI: 10.1038/bjc.2012.466] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
50 Lin ZZ, Hsu C, Hu FC, Shao YY, Chang DY, Yang CH, Hong RL, Hsu CH, Cheng AL. Factors impacting prognosis prediction in BCLC stage C and Child-Pugh class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy. Oncologist. 2012;17:970-977. [PMID: 22673633 DOI: 10.1634/theoncologist.2011-0411] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
51 Chen Z, Lin RM, Bai YK, Zhang Y. Establishment and Verification of Prognostic Nomograms for Patients with Gastrointestinal Stromal Tumors: A SEER-Based Study. Biomed Res Int 2019;2019:8293261. [PMID: 31032364 DOI: 10.1155/2019/8293261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
52 Kariyama K, Nouso K, Hiraoka A, Wakuta A, Oonishi A, Kuzuya T, Toyoda H, Tada T, Tsuji K, Itobayashi E, Ishikawa T, Takaguchi K, Tsutsui A, Shimada N, Kudo M, Kumada T. EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis. Liver Cancer 2020;9:734-43. [PMID: 33442542 DOI: 10.1159/000508971] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
53 Gao X, Lu C, Xie F, Li L, Liu M, Fang Z, Wang Z, Ming S, Dong H, Shen R, Sun Y, Peng Y, Gao X. Risk factors for sepsis in patients with struvite stones following percutaneous nephrolithotomy. World J Urol 2020;38:219-29. [DOI: 10.1007/s00345-019-02748-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
54 Saeki I, Yamasaki T, Tanabe N, Iwamoto T, Matsumoto T, Urata Y, Hidaka I, Ishikawa T, Takami T, Yamamoto N. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy. PLoS One. 2015;10:e0126649. [PMID: 25992784 DOI: 10.1371/journal.pone.0126649] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
55 Zhao LY, Wang JJ, Zhao YL, Chen XZ, Yang K, Chen XL, Zhang WH, Liu K, Song XH, Zheng JB, Zhou ZG, Yu PW, Li Y, Hu JK. Superiority of Tumor Location-Modified Lauren Classification System for Gastric Cancer: A Multi-Institutional Validation Analysis.Ann Surg Oncol. 2018;25:3257-3263. [PMID: 30051368 DOI: 10.1245/s10434-018-6654-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
56 Franck M, Schütte K, Malfertheiner P, Link A. Prognostic value of serum microRNA-122 in hepatocellular carcinoma is dependent on coexisting clinical and laboratory factors. World J Gastroenterol 2020;26:86-96. [PMID: 31933516 DOI: 10.3748/wjg.v26.i1.86] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Huang G, Jiang H, Lin Y, Wu Y, Cai W, Shi B, Luo Y, Jian Z, Zhou X. Prognostic value of plasma fibrinogen in hepatocellular carcinoma: a meta-analysis. Cancer Manag Res 2018;10:5027-41. [PMID: 30464603 DOI: 10.2147/CMAR.S175780] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
58 Adhoute X, Pénaranda G, Raoul JL, Edeline J, Blanc JF, Pol B, Campanile M, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Le Treut YP, Bronowicki JP, Bourlière M. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort. World J Gastroenterol 2017;23:2545-55. [PMID: 28465639 DOI: 10.3748/wjg.v23.i14.2545] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
59 Samawi HH, Sim HW, Chan KK, Alghamdi MA, Lee-Ying RM, Knox JJ, Gill P, Romagnino A, Batuyong E, Ko YJ, Davies JM, Lim HJ, Cheung WY, Tam VC; CHORD Consortium. Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database. Cancer Med 2018. [PMID: 29766659 DOI: 10.1002/cam4.1493] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
60 Liu CY, Chen KF, Chen PJ. Treatment of Liver Cancer. Cold Spring Harb Perspect Med 2015;5:a021535. [PMID: 26187874 DOI: 10.1101/cshperspect.a021535] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 14.2] [Reference Citation Analysis]
61 Yin X, She H, Martin Kasyanju Carrero L, Ma W, Zhou B. Nomogram prediction for the overall survival and cancer-specific survival of patients diagnosed with Merkel cell carcinoma. Ann Transl Med 2021;9:286. [PMID: 33708913 DOI: 10.21037/atm-20-4578] [Reference Citation Analysis]
62 Du Y, Han X, Ding YB, Yin JH, Cao GW. Prediction and prophylaxis of hepatocellular carcinoma occurrence and postoperative recurrence in chronic hepatitis B virus-infected subjects. World J Gastroenterol 2016;22:6565-72. [PMID: 27547000 DOI: 10.3748/wjg.v22.i29.6565] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Yang J, Bao Y, Chen W, Duan Y, Sun D. Nomogram Based on Systemic Immune Inflammation Index and Prognostic Nutrition Index Predicts Recurrence of Hepatocellular Carcinoma After Surgery. Front Oncol 2020;10:551668. [PMID: 33163397 DOI: 10.3389/fonc.2020.551668] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Liao W, Liu W, Liu X, Yuan Q, Ou Y, Qi Y, Huang W, Wang Y, Huang J. Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma. Oncotarget 2015;6:24132-47. [PMID: 26125229 DOI: 10.18632/oncotarget.4432] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
65 Zhang JF, Shu ZJ, Xie CY, Li Q, Jin XH, Gu W, Jiang FJ, Ling CQ. Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort. PLoS One. 2014;9:e88182. [PMID: 24609114 DOI: 10.1371/journal.pone.0088182] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
66 Kudo M, Trevisani F, Abou-Alfa GK, Rimassa L. Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment. Liver Cancer. 2016;6:16-26. [PMID: 27995084 DOI: 10.1159/000449343] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 13.0] [Reference Citation Analysis]
67 Chen ZH, Hong YF, Lin J, Li X, Wu DH, Wen JY, Chen J, Ruan DY, Lin Q, Dong M, Wei L, Wang TT, Lin ZX, Ma XK, Wu XY, Xu R. Validation and ranking of seven staging systems of hepatocellular carcinoma. Oncol Lett 2017;14:705-14. [PMID: 28693224 DOI: 10.3892/ol.2017.6222] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
68 Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma 2017;4:93-103. [PMID: 28744453 DOI: 10.2147/JHC.S106529] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
69 Takagi K, Domagala P, Polak WG, Buettner S, Ijzermans JNM. Prognostic significance of the controlling nutritional status (CONUT) score in patients undergoing hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterol 2019;19:211. [PMID: 31818259 DOI: 10.1186/s12876-019-1126-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
70 Chan SL, Yeo W. Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights. World J Gastroenterol. 2014;20:3135-3145. [PMID: 24696599 DOI: 10.3748/wjg.v20.i12.3135] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
71 Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Uesaka K. The optimal cut-off value of the preoperative prognostic nutritional index for the survival differs according to the TNM stage in hepatocellular carcinoma. Surg Today 2017;47:986-93. [PMID: 28315008 DOI: 10.1007/s00595-017-1491-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
72 Zhang MX, Gan W, Jing CY, Zheng SS, Yi Y, Zhang J, Xu X, Lin JJ, Zhang BH, Qiu SJ. S100A11 promotes cell proliferation via P38/MAPK signaling pathway in intrahepatic cholangiocarcinoma. Mol Carcinog 2019;58:19-30. [PMID: 30182496 DOI: 10.1002/mc.22903] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
73 Du X, Guo CN, Bao XD. A Powerful Nomogram Based on the Novel D-Index to Predict Prognosis After Surgical Resection of Hepatocellular Carcinoma. Cancer Manag Res 2021;13:2581-94. [PMID: 33762849 DOI: 10.2147/CMAR.S305253] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Su L, Zhou T, Zhang Z, Zhang X, Zhi X, Li C, Wang Q, Jia C, Shi W, Yue Y, Gao Y, Cheng B. Optimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: a retrospective study. BMC Cancer 2016;16:424. [PMID: 27387757 DOI: 10.1186/s12885-016-2420-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
75 Huang ZD, Yao YY, Chen TY, Zhao YF, Zhang C, Niu YM. Construction of Prognostic Risk Prediction Model of Oral Squamous Cell Carcinoma Based on Nine Survival-Associated Metabolic Genes. Front Physiol 2021;12:609770. [PMID: 33815132 DOI: 10.3389/fphys.2021.609770] [Reference Citation Analysis]
76 Ang SF, Ng ES, Li H, Ong YH, Choo SP, Ngeow J, Toh HC, Lim KH, Yap HY, Tan CK, Ooi LL, Cheow PC, Chung AY, Chow PK, Foo KF, Tan MH. The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma. PLoS One. 2015;10:e0118658. [PMID: 25830231 DOI: 10.1371/journal.pone.0118658] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
77 Zhang MX, Gan W, Jing CY, Zheng SS, Yi Y, Zhang J, Xu X, Lin JJ, Zhang BH, Qiu SJ. High expression of Oct4 and Nanog predict poor prognosis in intrahepatic cholangiocarcinoma patients after curative resection. J Cancer 2019;10:1313-24. [PMID: 30854141 DOI: 10.7150/jca.28349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
78 Zhang S, Tong YX, Zhang XH, Zhang YJ, Xu XS, Xiao AT, Chao TF, Gong JP. A novel and validated nomogram to predict overall survival for gastric neuroendocrine neoplasms. J Cancer 2019;10:5944-54. [PMID: 31762804 DOI: 10.7150/jca.35785] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
79 Dong W, Yan K, Yu H, Huo L, Xian Z, Zhao Y, Li J, Zhang Y, Cao Z, Fu Y, Cong W, Dong H. Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy. Front Oncol 2020;10:605057. [PMID: 33643907 DOI: 10.3389/fonc.2020.605057] [Reference Citation Analysis]
80 Okamura Y, Ashida R, Ito T, Sugiura T, Mori K, Uesaka K. Preoperative Neutrophil to Lymphocyte Ratio and Prognostic Nutritional Index Predict Overall Survival After Hepatectomy for Hepatocellular Carcinoma. World J Surg 2015;39:1501-9. [DOI: 10.1007/s00268-015-2982-z] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 12.3] [Reference Citation Analysis]
81 Lué A, Serrano MT, Bustamante FJ, Iñarrairaegui M, Arenas JI, Testillano M, Lorente S, Gil C, de la Torre M, Gomez A, Sangro B. Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib. Oncotarget 2017;8:103077-86. [PMID: 29262546 DOI: 10.18632/oncotarget.21528] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
82 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014] [Reference Citation Analysis]
83 Bu Y, Liu F, Jia QA, Yu SN. Decreased Expression of TMEM173 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma. PLoS One 2016;11:e0165681. [PMID: 27814372 DOI: 10.1371/journal.pone.0165681] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
84 Sceusi EL, Loose DS, Wray CJ. Clinical implications of DNA methylation in hepatocellular carcinoma. HPB (Oxford). 2011;13:369-376. [PMID: 21609368 DOI: 10.1111/j.1477-2574.2011.00303.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 4.5] [Reference Citation Analysis]
85 Ziogas IA, Tsoulfas G. Advances and challenges in laparoscopic surgery in the management of hepatocellular carcinoma. World J Gastrointest Surg 2017;9:233-45. [PMID: 29359029 DOI: 10.4240/wjgs.v9.i12.233] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
86 Zhang X, Yang H, Yue S, He G, Qu S, Zhang Z, Ma B, Ding R, Peng W, Zhang H, Yang Z, Dou K, Tao K, Li X. The mTOR inhibition in concurrence with ERK1/2 activation is involved in excessive autophagy induced by glycyrrhizin in hepatocellular carcinoma. Cancer Med 2017;6:1941-51. [PMID: 28675698 DOI: 10.1002/cam4.1127] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
87 Harding JJ, Khalil DN, Abou-Alfa GK. Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma? Dig Dis Sci 2019;64:918-27. [PMID: 30838478 DOI: 10.1007/s10620-019-05517-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
88 Zhang Y, Chen XL, Chen WM, Zhou HB. Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma. Biomed Res Int 2019;2019:5652935. [PMID: 31080823 DOI: 10.1155/2019/5652935] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
89 Zhou S, Yan Y, Chen X, Zeng S, Wei J, Wang X, Gong Z, Xu Z. A two-gene-based prognostic signature for pancreatic cancer. Aging (Albany NY) 2020;12:18322-42. [PMID: 32966237 DOI: 10.18632/aging.103698] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
90 Lee IC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lin HC, Lee FY, Huang YH. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. Medicine (Baltimore). 2015;94:e688. [PMID: 25860213 DOI: 10.1097/md.0000000000000688] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
91 Wu M, Hu Y, Ren A, Peng X, Ma Q, Mao C, Hang J, Li A. Nomogram Based on Ultrasonography and Clinical Features for Predicting Malignancy in Soft Tissue Tumors. Cancer Manag Res 2021;13:2143-52. [PMID: 33688257 DOI: 10.2147/CMAR.S296972] [Reference Citation Analysis]
92 Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-58. [PMID: 24159579 DOI: 10.1159/000343828] [Cited by in Crossref: 169] [Cited by in F6Publishing: 157] [Article Influence: 24.1] [Reference Citation Analysis]
93 Signoriello S, Annunziata A, Lama N, Signoriello G, Chiodini P, De Sio I, Daniele B, Di Costanzo GG, Calise F, Olivieri G, Castaldo V, Lanzetta R, Piai G, Marone G, Visconti M, Fusco M, Di Maio M, Perrone F, Gallo C, Gaeta GB. Survival after locoregional treatments for hepatocellular carcinoma: a cohort study in real-world patients. ScientificWorldJournal. 2012;2012:564706. [PMID: 22654628 DOI: 10.1100/2012/564706] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
94 Li Q, Li S, Wu Y, Gao F. miRNA-708 functions as a tumour suppressor in hepatocellular carcinoma by targeting SMAD3. Oncol Lett 2017;14:2552-8. [PMID: 28789462 DOI: 10.3892/ol.2017.6429] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
95 Wu C, Wu Z, Tian B. Five gene signatures were identified in the prediction of overall survival in resectable pancreatic cancer. BMC Surg 2020;20:207. [PMID: 32943033 DOI: 10.1186/s12893-020-00856-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Yan X, Wan H, Hao X, Lan T, Li W, Xu L, Yuan K, Wu H. Importance of gene expression signatures in pancreatic cancer prognosis and the establishment of a prediction model. Cancer Manag Res 2019;11:273-83. [PMID: 30643453 DOI: 10.2147/CMAR.S185205] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
97 Kinoshita A, Onoda H, Takano K, Imai N, Saeki C, Fushiya N, Miyakawa Y, Nishino H, Tajiri H. Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma. Med Oncol. 2012;29:2800-2808. [PMID: 22460836 DOI: 10.1007/s12032-012-0220-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
98 Wang H, Peng Y, Huang Q, Wu J, Zhang M. Prognostic Nomograms for Nonelderly Adults with Gastric Signet Ring Cell Carcinoma. Biomed Res Int 2021;2021:1274527. [PMID: 33834061 DOI: 10.1155/2021/1274527] [Reference Citation Analysis]
99 Liu Z, Gao P, Liu S, Zheng G, Yang J, Sun L, Hong L, Fan D, Zhang H, Feng F. Tumor volume increases the predictive accuracy of prognosis for gastric cancer: A retrospective cohort study of 3409 patients. Oncotarget. 2017;8:18968-18978. [PMID: 28145885 DOI: 10.18632/oncotarget.14859] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
100 Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Fushiya N, Koike K, Nishino H, Tajiri H. Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br J Cancer. 2012;107:988-993. [PMID: 22878374 DOI: 10.1038/bjc.2012.354] [Cited by in Crossref: 168] [Cited by in F6Publishing: 174] [Article Influence: 18.7] [Reference Citation Analysis]
101 Song C, Yu D, Wang Y, Wang Q, Guo Z, Huang J, Li S, Hu W. Dual Primary Cancer Patients With Lung Cancer as a Second Primary Malignancy: A Population-Based Study. Front Oncol 2020;10:515606. [PMID: 33194578 DOI: 10.3389/fonc.2020.515606] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
102 Memon K, Kulik LM, Lewandowski RJ, Wang E, Wang J, Ryu RK, Hickey R, Vouche M, Baker T, Ganger D. Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization. J Vasc Interv Radiol. 2014;25:1056-1066. [PMID: 24613269 DOI: 10.1016/j.jvir.2014.01.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
103 Yang L, Yin W, Liu X, Li F, Ma L, Wang D, Li H. Identification of a five-gene signature in association with overall survival for hepatocellular carcinoma. PeerJ 2021;9:e11273. [PMID: 33986994 DOI: 10.7717/peerj.11273] [Reference Citation Analysis]
104 Zhou DS, Xu L, Luo YL, He FY, Huang JT, Zhang YJ, Chen MS. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization. World J Gastroenterol. 2015;21:5582-5590. [PMID: 25987783 DOI: 10.3748/wjg.v21.i18.5582] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
105 Pinato DJ, North BV, Sharma R. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br J Cancer. 2012;106:1439-1445. [PMID: 22433965 DOI: 10.1038/bjc.2012.92] [Cited by in Crossref: 209] [Cited by in F6Publishing: 207] [Article Influence: 23.2] [Reference Citation Analysis]
106 Qiao G, Cucchetti A, Li J, Cescon M, Ercolani G, Liu G, Pinna AD, Li L, Shen F, Ren J. Applying of pretreatment extent of disease system in patients with hepatocellular carcinoma after curative partial hepatectomy. Oncotarget 2016;7:30408-19. [PMID: 27007152 DOI: 10.18632/oncotarget.8149] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
107 Hu K, Wang J, Yao Z, Liu B, Lin Y, Liu L, Xu L. Expression of cytoskeleton regulatory protein Mena in human hepatocellular carcinoma and its prognostic significance. Med Oncol 2014;31:939. [PMID: 24683008 DOI: 10.1007/s12032-014-0939-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
108 Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S, Abbruzzese JL. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 2011;29:3892-9. [PMID: 21911725 DOI: 10.1200/JCO.2011.36.0636] [Cited by in Crossref: 83] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
109 He CB, Lin XJ. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101. PLoS One 2017;12:e0174769. [PMID: 28355305 DOI: 10.1371/journal.pone.0174769] [Cited by in Crossref: 22] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
110 Zhao LY, Chen XL, Wang YG, Xin Y, Zhang WH, Wang YS, Chen XZ, Yang K, Liu K, Xue L, Zhang B, Chen ZX, Chen JP, Zhou ZG, Hu JK. A new predictive model combined of tumor size, lymph nodes count and lymphovascular invasion for survival prognosis in patients with lymph node-negative gastric cancer. Oncotarget. 2016;7:72300-72310. [PMID: 27509175 DOI: 10.18632/oncotarget.11035] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
111 Zhang Y, Zhang J, Zeng H, Zhou XH, Zhou HB. Nomograms for predicting the overall and cancer-specific survival of patients with classical Hodgkin lymphoma: a SEER-based study. Oncotarget 2017;8:92978-88. [PMID: 29190971 DOI: 10.18632/oncotarget.21722] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
112 Zhuang L, Xu L, Wang P, Meng Z. Serum miR-128-2 serves as a prognostic marker for patients with hepatocellular carcinoma. PLoS One. 2015;10:e0117274. [PMID: 25642945 DOI: 10.1371/journal.pone.0117274] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
113 Kaseb AO, Shah NN, Hassabo HM, Morris JS, Xiao L, Abaza YM, Soliman K, Lee JS, Vauthey JN, Wallace M. Reassessing hepatocellular carcinoma staging in a changing patient population. Oncology. 2014;86:63-71. [PMID: 24401634 DOI: 10.1159/000356573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
114 Liao R, Peng C, Li M, Li DW, Jiang N, Li PZ, Ding X, Wu Q, Du CY, Gong JP. Comparison and validation of the prognostic value of preoperative systemic immune cells in hepatocellular carcinoma after curative hepatectomy. Cancer Med 2018;7:1170-82. [PMID: 29533004 DOI: 10.1002/cam4.1424] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
115 Zhang H, Liang H, Gao Y, Shang X, Gong L, Ma Z, Sun K, Tang P, Yu Z. Metastatic lymph node ratio demonstrates better prognostic stratification than pN staging in patients with esophageal squamous cell carcinoma after esophagectomy. Sci Rep 2016;6:38804. [PMID: 27941828 DOI: 10.1038/srep38804] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
116 Song CK, Guo ZX, Shen XY, Wang YJ, Wang QW, Yu DH, Chen C, Liu XP, Huang JY, Li S, Hu W. Prognostic Factors Analysis and Nomogram Construction of Dual Primary Lung Cancer: A Population Study. Biomed Res Int 2020;2020:7206591. [PMID: 32149127 DOI: 10.1155/2020/7206591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Zhao LY, Zhao YL, Wang JJ, Zhao QD, Yi WQ, Yuan Q, Chen XZ, Li Y, Yang K, Chen XL, Zhang WH, Liu K, Pang HY, Galiullin D, Wang H, Sun LF, Song XH, Zheng JB, Yao XQ, Zhou ZG, Yu PW, Hu JK. Is Preoperative Fibrinogen Associated with the Survival Prognosis of Gastric Cancer Patients? A Multi-centered, Propensity Score-Matched Retrospective Study. World J Surg 2020;44:213-22. [PMID: 31637507 DOI: 10.1007/s00268-019-05191-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
118 Chan SL, Johnson PJ, Mo F, Berhane S, Teng M, Chan AW, Poon MC, Lai PB, Yu S, Chan AT. International validation of the Chinese university prognostic index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. Chin J Cancer. 2014;33:481-491. [PMID: 25223914 DOI: 10.5732/cjc.014.10133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]